Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis Authors: Miguel-Angel Perales, MD; Farrukh T. Awan, MD, MS; Ariane Boumendil, PhD; Jinalben Patel, BSc, MPH; Luca Castagna, MD; Emanuele Angelucci, MD; Herve Finel; Alexander D. Kulagin, MD; Bertram Glass, MD; Paolo Corradini, MD; Alex F. Herrera, MD; Didier Blaise, MD, HDR; Mohamed A. Kharfan-Dabaja, MD, MBA; Khalid Halahleh, MD; Sairah Ahmed, MD; Carmen Martínez, MD, PhD; Sebastian Giebel, MD, PhD; Silvia Montoto, MD, PhD; Richard J. Jones, MD; Nausheen Ahmed, MBBS; Ryan C. Lynch, MD; Marcos J. De Lima, MD; Mayzar Shadman, MD, MPH; Craig S. Sauter, MD; Kwang Woo Ahn, PhD; Mehdi Hamadani, MD; Ali Bazarbachi, MD, PhD; Anna Sureda, MD, PhD

https://www.medscape.org/viewarticle/1002843